An open-label, investigator-sponsored, Phase 2 study of ISIS-TTRRx in patients with transthyretin amyloid-related cardiomyopathy which includes patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin (wt-TTR) amyloidosis
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Therapeutic Use
- 26 Mar 2018 According to the Ionis Pharmaceuticals media release, new data from this study will be presented at the 16th International Symposium on Amyloidosis (ISA) 2018.
- 26 Mar 2018 Results presented in the Ionis Pharmaceuticals media release.
- 16 Aug 2016 New trial record